BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-78@catalystbrief.girapphe.com
DTSTAMP:20261117T061555Z
LAST-MODIFIED:20261117T061555Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Readout: Fujian Shengdi Pharmaceutical Co.\, Ltd. — HRS9531 injec
 tion [Mar 2027]
DESCRIPTION:Phase 3 primary completion: A Study Comparing the Efficacy and 
 Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Ob
 esity.\nSource: https://clinicaltrials.gov/study/NCT07285902\nhttps://cata
 lystbrief.girapphe.com/e/78?lang=en\nNot investment advice. Dates may chan
 ge.
URL:https://catalystbrief.girapphe.com/e/78?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
